Ipamorelin and HGH Fragment 176-191: How the Stack Is Usually Structured

What Each One Actually Is

Ipamorelin is a growth hormone secretagogue, a pentapeptide that binds the ghrelin receptor and prompts your own pituitary to release a pulse of growth hormone. It is described as selective because, unlike older GHRPs, it has minimal effect on cortisol and prolactin at typical doses. Because it works upstream on your own pituitary, the downstream consequence is a rise in growth hormone and, over weeks, in IGF-1.

HGH Fragment 176-191 is not a secretagogue at all. It is a synthetic peptide corresponding to the C-terminal region of the human growth hormone molecule, amino acids 176 through 191. That fragment is the region associated with growth hormone's fat-metabolizing activity, isolated away from the portion responsible for the growth-promoting signal.

The mechanistically important consequence, and the reason the pairing exists: Fragment 176-191 is not expected to raise IGF-1. It was studied as a way to pursue the lipolytic effect without the IGF-1 and insulin-sensitivity consequences that come with full growth hormone. Ipamorelin raises IGF-1. The fragment does not.

A necessary caveat. The human evidence base for Fragment 176-191 is thin. Most of what is claimed for it traces back to preclinical work, and it is not an FDA-approved product for human use. Treat confident claims about it, this page included, as a description of what the literature says rather than a promise about what it does in you.

Why the Timing Differs

The two compounds have different half-lives, and that is what drives the schedule.

Ipamorelin has a reported half-life in the range of roughly two hours. Its purpose is to produce a pulse, and pulsatile exposure is what keeps pituitary cells responsive, whereas continuous exposure tends to blunt the response. Most protocols place it away from food, because elevated glucose and insulin blunt growth hormone release, and often at bedtime so the dose layers on top of the body's own largest natural growth hormone pulse in early slow-wave sleep.

Fragment 176-191 has a much shorter reported half-life, commonly cited at around 30 minutes or less. Protocols usually place it fasted and often before activity, on the reasoning that the window is short and better used when fat oxidation is already elevated.

This is why the stack tends to end up split across the day rather than combined into one injection. The two compounds want different windows.

A Typical Structure

What people commonly describe, presented as a pattern and not a recommendation:

|---|---|---|

Every number in that table is community-reported rather than prescriptive, and dose ranges in particular vary widely between sources. The fasting convention is the part with the clearest mechanistic rationale behind it.

What to Track, and Why

The stack is unusual in that the two halves have different readouts. Tracking them together is the only way to tell which one is doing what.

IGF-1 is the readout for the ipamorelin half. Growth hormone is pulsatile and clears in minutes, so measuring it directly is nearly useless outside a stimulation test. IGF-1 is stable across the day because most of it travels bound in a complex with a half-life of roughly 12 to 16 hours, which is what makes it the practical gauge. It is a lagging indicator: it moves over weeks, not days, which is why a check around the six-week mark is more informative than one at week two.

A caution that trips people up. Drawing IGF-1 within hours of a dose inflates the number. Draw fasted, in the morning, at a consistent interval after your last dose, and use the same lab every time. Between-lab assay differences are real, and a 30 ng/mL move between two different labs may be method rather than biology.

Fasting glucose, fasting insulin, and HbA1c. Growth hormone is counter-regulatory to insulin. A rising IGF-1 that reads like progress can be accompanied by a quiet slide in insulin sensitivity, and you will not see it unless you are looking. This is the single most useful thing to pair with IGF-1 on any GH-directed protocol.

IGFBP-3 adds context to an IGF-1 reading, since it is the main binding protein and generally moves in parallel.

Body composition, measured the same way each time. Since the fragment half of the stack is aimed at fat metabolism and is not expected to move IGF-1, composition is where its signal would show up if it shows up anywhere. Same scale, same time of day, same conditions, or noise swamps the trend.

What Commonly Goes Wrong

Eating too close to the dose. Elevated glucose and insulin blunt growth hormone release. A dose taken 20 minutes after dinner is working against itself.

Drawing labs at the wrong time. Covered above, and worth repeating because it is the most common way people end up with an uninterpretable number.

Expecting the fragment to move IGF-1. It is not supposed to. If you are judging the fragment by IGF-1, you are using the wrong instrument.

Chasing a higher IGF-1. Higher is not automatically better. Population data relates IGF-1 to mortality in a U-shape, with elevated risk at both the low and the high end, and higher circulating IGF-1 has been associated in large prospective cohorts with modestly increased risk of certain cancers. That trade belongs in a conversation with a clinician, not a spreadsheet.

Changing both halves at once. If you adjust ipamorelin and the fragment in the same week, you have given up the ability to attribute whatever happens next.

Related

---

*MyProtocolStack is a tracking and education tool. It does not diagnose, treat, or prescribe. Compounds described here are research and educational references, and several are not approved for human use. Every dosing figure above is community-reported rather than prescriptive. Any protocol decision belongs with a licensed healthcare provider.*